Flagship Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Flagship Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11.1K	Hold	200	–	–	﹤0.01%	379
2026 Q2	$10.9K	Hold	200	–	–	﹤0.01%	396
2026 Q1	$9.7K	Hold	200	–	–	﹤0.01%	285
2025 Q4	$10.5K	Hold	200	–	–	﹤0.01%	326
2025 Q3	$13K	Hold	200	–	–	﹤0.01%	312
2025 Q2	$9.7K	Hold	200	–	–	﹤0.01%	300
2025 Q1	$6.81K	Hold	200	–	–	﹤0.01%	319
2024 Q4	$7.87K	Buy	+200	New	+$9.44K	﹤0.01%	303

Other funds holding CRSP

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Flagship Wealth Advisors's CRSP Position: Q3 2026 in Review

Flagship Wealth Advisors held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 200 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #379.

Flagship Wealth Advisors first reported a position in CRSP in Q4 2024 and has held it in 8 quarters since. The position peaked at $13K in Q3 2025. 340 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

Flagship Wealth Advisors held 200 shares of CRISPR Therapeutics worth $11.1K as of Q3 2026.
Flagship Wealth Advisors left its CRISPR Therapeutics share count unchanged in Q3 2026.
CRISPR Therapeutics made up ﹤0.01% of Flagship Wealth Advisors's portfolio in Q3 2026, its #379 holding.
Flagship Wealth Advisors first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 8 quarters since.
Flagship Wealth Advisors's CRISPR Therapeutics position peaked at $13K in Q3 2025.
340 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Flagship Wealth Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.